title: Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty.
abstract: Background. Gonadotropin releasing hormone analogs (GnRHas) are standard of care for central precocious puberty (CPP). The histrelin subcutaneous implant is safe and effective in the treatment of CPP for one year. Objective. The study evaluates a second year of therapy in children with CPP who received a new implant after one year of treatment. Methods. A prospective one-year study following an initial 12-month treatment period was conducted. Results. Thirty-one patients (29 girls) aged 7.7 +/- 1.5 years received a second implant. Eighteen were naïve to GnRHa therapy at first implantation. Peak LH declined from 0.92 +/- 0.58 mIU/mL at 12 months to 0.51 +/- 0.33 mIU/mL at 24 months (P < .0001) in naïve subjects, and from 0.74 +/- 0.50 mIU/mL at 12 months to 0.45 +/- 0.35 mIU/mL at 24 months (P = .0081) in previously treated subjects. Predicted adult height increased by 5.1 cm at 24 months (P = .0001). Minor implant site reactions occurred in 61%, while minor difficulties with explantation occurred in 32.2% of subjects. Conclusion. The histrelin implant demonstrates profound hypothalamic-pituitary-gonadal axis suppression when a new implant is placed for a second year of treatment. Prospective follow-up of this therapeutic modality for the treatment of CPP is needed.
authors: Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
authors: Samar
authors: S
authors: Rahhal
authors: William L
authors: WL
authors: Clarke
authors: Gad B
authors: GB
authors: Kletter
authors: Peter A
authors: PA
authors: Lee
authors: E Kirk
authors: EK
authors: Neely
authors: Edward O
authors: EO
authors: Reiter
authors: Paul
authors: P
authors: Saenger
authors: Dorothy
authors: D
authors: Shulman
authors: Lawrence
authors: L
authors: Silverman
authors: Erica A
authors: EA
authors: Eugster